Expert consensus on the diagnosis and management of alcoholic liver disease


  • Prashant Solanki Tirupati Liver and Gastro Care Center, Meerut, Uttar Pradesh, India



ALD, Liver biopsy, Alcohol abstinence, Microbiota-based precision medicine, UDCA


Alcoholic liver disease (ALD) is a spectrum of liver injuries caused due to harmful use of alcohol. It is the primary cause of liver disease and is responsible for around 4% of mortality worldwide. ALD progresses from fatty liver to alcoholic hepatitis depending upon risk factors, such as continued alcohol consumption or comorbid liver diseases. Screening and diagnosis are suggested for patients with histological symptoms and in high-risk populations. Management of ALD includes strategies such as abstinence from alcohol consumption, nutrition therapy, pharmacological therapy, and liver transplantation, with alcohol abstinence being the most beneficial to reverse fatty liver conditions. Various novel treatment approaches having distinct mechanisms of action are also developed besides conventional corticosteroid therapy, which include microbiota-based precision medicine, monoclonal antibody therapy, hepatocyte regeneration therapy, epigenetic modulators, liver degeneration boosters, and targeting the gut-liver axis. Ursodeoxycholic acid (UDCA) has shown to benefit ALD patients with cholestasis by exerting biochemical improvements; hence, it can be considered as an adjunct therapy. National and regional advisory board meetings were conducted to discuss the current diagnostic and management techniques, including existing and novel pharmacological treatments available for ALD along with current clinical practices in India.


Metrics Loading ...


Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-related liver diseases: 2019 practice guidance from the American association for the study of liver diseases. Hepatology. 2020;71:306-33.

Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Trans Gastro Hepato. 2020;5:1-17.

EASL clinical practical guidelines: Management of alcoholic liver disease. J Hepatol. 2012;57:399-420.

Johnson KD, Yee EU, Laoveeravat P, Perisetti A, Thandassery RB, Tharian B. Endoscopic ultrasound guided liver biopsy: Recent evidence. World J Gastrointest Endosc 2020;12:83-97.

Torruellas C, French S, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol. 2014;20:11684-99.

Mueller S, Sandrin L. Liver stiffness: A novel parameter for the diagnosis of liver disease. Hepat Med 2010;2:49-67.

Marsano LS, Mendez C, Hill D, Barve S, McClain CJ. Diagnosis and treatment of alcoholic liver disease and its complications. Alcohol Res Health. 2003;27:247-56.

Maher JJ. Alcoholic steatohepatitis: Management and prognosis. Curr Gastroenterol Rep. 2007;9:39-46.

O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatol. 2010;51:307-28.

Tijera FH, Servin-Caamano AI, Cruz-Herrera J, Serralde- Zuniga AE, Perez-Torres E, Abdo-Francis JM et al. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol. 2015;21:4975-85.

Shasthry SM. Fecal microbiota transplantation in alcohol related liver diseases. Clin Mol Hepatol. 2020;26(3):294-301.

Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Albanese A et al. S-Adenosylmethionine treatment of alcoholic liver disease: A double-blind, randomized, placebo-controlled trial. Alcohol Clin Exp Res. 2011;35:1960-5.

Lieber CS. S-Adenosyl-L-methionine: Its role in the treatment of liver disorders. Amer J Clini Nutr. 2002;76:1183S-7S.

Nanji AA, Yang EK, Fogt F, Sadrzadeh SM, Dannenberg AJ. Medium chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease. J Pharmacol Exp Ther. 1996;277:1694-700.

Tung B Y, Carithers Jr R L. Cholestasis and alcoholic liver disease. Clin Liv Dis. 1999;3:585-601.

Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liv Dis. 2004;8:67-81.

Pelvris JN, Hayes PC, Bouchier IAD, Pelvris J. Ursodeoxycholic acid in the treatment of alcoholic liver-disease. Eur J Gastroenterol Hepatol. 1991;3:653-6.

David T, Gynogyi S. Emerging medical therapies for severe alcoholic hepatitis. Clin Mol Hepatol. 2020;26:686-96.

Philips CA, Augustine P, Ganesan K, Ranade S, Chopra V, Patil K et al. The role of gut microbiota in clinical complications, disease severity, and treatment response in severe alcoholic hepatitis. Indian J Gastroenterol. 2022;41:37-51.

Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immun. 2020;18:73-91.






Review Articles